Device: Desktop
|
Home
Innovation
Mission
Latest News
Meet Us
Management Team
Corporate Team
Key R&D Team
Board of Directors
Scientific Advisory Board
Science
Molecular Target
Mechanism of Action
Aelis Farma's Targets
Pipeline
AEF0117
AEF0217
New CB
1
-SSi
Partners
News
Contact
Investors
fr
Menu
Home
Meet Us
Science
Pipeline
Partners
News
Contact
Investors
Français
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB
1
(CB
1
-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
+
more info
Aelis Farma’s Mission
”
To combine the scientific breakthrough of CB
1
with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
“
Pier Vincenzo Piazza, CEO
Download our corporate presentation
+
more info
Latest News
Visite our news page
Latest News
Results of the clinical Phase 2B Study with AEF0117 in Cannabis Use Disorder
September 2024
+
Aelis Farma announces the Last Patient, Last Visit in its clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder
April 2024
+